(Q35040973)

6 August 2017

1 reference

title

Childhood nasopharyngeal carcinoma: from biology to treatment (English)

1 reference

6 August 2017

Inci Ayan

1

1 reference

6 August 2017

Esra Kaytan

series ordinal

2

1 reference

6 August 2017

Nihat Ayan

series ordinal

3

1 reference

6 August 2017

publication date

1 January 2003

1 reference

Lancet Oncology Commission

6 August 2017

published in

1 reference

6 August 2017

volume

4

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

13-21

1 reference

Nasopharyngeal carcinoma in the young: a combined M.D. Anderson and Stanford experience

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

Pediatric nasopharyngeal carcinoma: long term follow-up of 29 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

Nasopharyngeal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

Nasopharyngeal carcinoma in childhood

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

Cancer of the nasopharynx in children

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

Nasopharyngeal carcinoma in children: retrospective review of 50 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

Undifferentiated nasopharyngeal cancer (UCNT): current diagnostic and therapeutic aspects

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

Tumors of the nasopharynx in Tunisia.An anatomic and clinical study based on 143 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

Demographic patterns for nasopharyngeal carcinoma in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

Nasopharyngeal carcinoma in young patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

Cancer of the nasopharynx. Factors influencing prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

Nasopharyngeal carcinoma at the Tel-Hashomer Government Hospital, Israel. A 20 year survey (1951-1970).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

Nasopharyngeal carcinoma in Uganda

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

CYP2E1 genetic polymorphisms and risk of nasopharyngeal carcinoma in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

Analysis of bcl-2 expression in normal, inflamed, dysplastic nasopharyngeal epithelia, and nasopharyngeal carcinoma: association with p53 expression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

Antibodies to the Epstein-Barr virus transactivator protein (ZEBRA) as a valuable biomarker in young patients with nasopharyngeal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

Nasopharyngeal carcinoma, with emphasis on its relationship to Epstein-Barr virus

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

Epstein-Barr virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

Detection of Epstein-Barr virus DNA sequences in nasopharyngeal carcinoma cells by enzymatic DNA amplification

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

Epstein-Barr virus DNA in nasopharyngeal carcinomas from Chinese patients in Hong Kong

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

Differences in the growth pattern and clinical course of EBV-LMP1 expressing and non-expressing nasopharyngeal carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

Expression of Epstein-Barr virus-encoded RNAs as a marker for metastatic undifferentiated nasopharyngeal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

Epstein Barr virus associated pediatric nasopharyngeal carcinoma: its correlation with p53 and bcl-2 expression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

Bcl-2 proto-oncogene expression in Epstein-Barr-virus-associated nasopharyngeal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

Nasopharyngeal carcinoma in childhood and adolescence: concept and preliminary results of the cooperative GPOH study NPC-91. Gesellschaft für Pädiatrische Onkologie und Hämatologie

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

Anatomic correlates of acoustic rhinometry as measured by rigid nasal endoscopy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

Three-dimensional photon treatment planning for carcinoma of the nasopharynx

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

Nasopharyngeal carcinoma--a retrospective review of patients less than thirty years of age: a report of Children's Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

Nasopharyngeal carcinoma in childhood and adolescence.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

Nasopharyngeal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

Improved long-term survival with combined modality therapy for pediatric nasopharynx cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

Nasopharyngeal carcinoma in children under 15 years of age: a retrospective review of 65 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

Nasopharyngeal carcinoma in the young

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

Treatment and outcome of undifferentiated carcinoma of the nasopharynx in childhood: a 13-year experience

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

Nasopharyngeal carcinoma in childhood: long-term results of 32 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

Interruptions adversely affect local control and survival with hyperfractionated radiation therapy of carcinomas of the upper respiratory and digestive tracts. New evidence for accelerated proliferation from Radiation Therapy Oncology Group Protocol

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

Final report of a randomized trial on altered-fractionated radiotherapy in nasopharyngeal carcinoma prematurely terminated by significant increase in neurologic complications.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

Treatment planning and delivery of intensity-modulated radiation therapy for primary nasopharynx cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV(> or = N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progr

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

Enhancement of local control in locally advanced node-positive nasopharyngeal carcinoma by adjunctive chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

Combined radiotherapy and chemotherapy in stage T3 and T4 nasopharyngeal carcinoma in children

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

Effective adjuvant chemotherapy for advanced nasopharyngeal carcinoma in children: a final update of a long-term prospective study in a single institution

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

Outpatient weekly chemotherapy in patients with nasopharyngeal carcinoma and distant metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

A phase II study of cisplatin/ifosfamide in recurrent/metastatic undifferentiated nasopharyngeal carcinoma among young blacks in southern Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900956-2

7 January 2021

10.1016/S1470-2045(03)00956-2

Identifiers

DOI

1 reference

6 August 2017

1 reference